UBS Group’s Rennova Health RNVA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-2,218
| Closed | -$6K | – | 8434 |
|
|
2017
Q3 | $6K | Buy |
2,218
+596
| +37% | +$2.55K | ﹤0.01% | 7190 |
|
|
2017
Q2 | $9K | Buy |
+1,622
| New | +$17.2K | ﹤0.01% | 6880 |
|
|
2016
Q4 | – | Sell |
-29
| Closed | -$2K | – | 8309 |
|
|
2016
Q3 | $2K | Buy |
29
+26
| +867% | +$3.41K | ﹤0.01% | 7466 |
|
|
2016
Q2 | $1K | Hold |
3
| – | – | ﹤0.01% | 7626 |
|
|
2016
Q1 | $1K | Sell |
3
-2
| -40% | -$735 | ﹤0.01% | 7518 |
|
|
2015
Q4 | $3K | Buy |
5
+3
| +150% | +$5.19K | ﹤0.01% | 7941 |
|
|
2015
Q3 | $5K | Buy |
2
+1
| +100% | +$2.72K | ﹤0.01% | 7762 |
|
|
2015
Q2 | $4K | Hold |
1
| – | – | ﹤0.01% | 8022 |
|
|
2015
Q1 | $5K | Buy |
+1
| New | +$5.2K | ﹤0.01% | 8150 |
|
|
2014
Q4 | – | Sell |
-1
| Closed | -$4K | – | 10649 |
|
|
2014
Q3 | $4K | Buy |
+1
| New | +$6.8K | ﹤0.01% | 9700 |
|
|
2014
Q2 | – | Sell |
-1
| Closed | -$12K | – | 11095 |
|
|
2014
Q1 | $12K | Buy |
+1
| New | +$15.8K | ﹤0.01% | 8734 |
|
|
2013
Q4 | – | Hold |
0
| – | – | – | 9926 |
|
|
2013
Q3 | – | Sell |
-1
| Closed | -$16.9K | – | 9478 |
|
|
2013
Q2 | $10K | Hold |
1
| – | – | ﹤0.01% | 8667 |
|
UBS Group's RNVA Position: Q4 2017 in Review
UBS Group sold out of Rennova Health (RNVA) in Q4 2017, closing a stake of 2,218 shares — an estimated $6K sold.
UBS Group first reported a position in RNVA in Q2 2013 and held it in 12 quarters. The position peaked at $12K in Q1 2014. 1 fund tracked by Wall St. Rank holds RNVA as of Q4 2017.
- UBS Group reported no remaining Rennova Health position as of Q4 2017 after selling out during the quarter.
- UBS Group sold 2,218 Rennova Health shares in Q4 2017, an estimated $6K.
- UBS Group first reported a position in Rennova Health in Q2 2013 and held it in 12 quarters.
- UBS Group's Rennova Health position peaked at $12K in Q1 2014.
- 1 fund tracked by Wall St. Rank held Rennova Health as of Q4 2017.
Based on UBS Group's 13F filing for Q4 2017, filed 14 Feb 2018.